Nasdaq rxrx
NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ...
Did you know?
Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...
Nov 26, 2023 · For a biotech like Recursion Pharmaceuticals (RXRX-2.63%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ... Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...RXRX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …
RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials News Ideas Technicals . Forecast . Price target. 12.33 0.00 0.00%. The 6 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —.Recursion Pharmaceuticals (NASDAQ:RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ...…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion P. Possible cause: Find the latest on option chains for Recursion Pha...
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share …
In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share …Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...
greer mcelveen funeral home and crematory Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa whinery savage funeral home obituariesaverage inseam for 5 Earnings Trend: RXRX is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year. Accelerating Growth: Unable to compare RXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable. Earnings vs Industry: RXRX is unprofitable, making it difficult to compare its past year earnings ...Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ... lebron 3 1 meme Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... best stock under dollar5bednerpercent27s farm animalszlecenia Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish.Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals ( RXRX 4.83%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... personalizestore Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» … skullmetro tmobileblogcraigslist chicago gigs labor Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues. Simply Wall St. Published December 09, 2023. Source: …
